Thiotepa (Thiotepa Injection) Drug Information: Clinical Pharmacology

Pill Identifier Search

May 27, 2012

thiotepa

Cancer »

What is cancer?

Cancer is the uncontrolled growth of abnormal cells anywhere in a body. The abnormal cells are termed cancer cells, malignant cells, or tumor cells. Many cancers and the abnormal cells that compose the cancer tissue are further identified by the name of the tissue that the abnormal cells originated from (for example, breast cancer, lung cancer, colon cancer). Cancer is not confined to humans; animals and other living organisms can get cancer. Below is a schematic that shows normal cell division and how when a cell is damaged or altered without repair to its system, the cell usually dies. Also shown is what can occur when such damaged or unrepaired cells do not die and become cancer cells and proliferate with uncontrolled growth; a mass of cancer cells develop. Frequently, cancer cells can break away from this original mass of cells, travel through the blood and lymph systems, and lodge in other organs where they can again repeat the ...

Read the Cancer article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Thiotepa

Breast Cancer Slideshow Pictures

Pancreatic Cancer Slideshow Pictures

Skin Cancer Slideshow Pictures

font size

CLINICAL PHARMACOLOGY

Thiotepa (thiotepa (thiotepa injection) injection) is a cytotoxic agent of the polyfunctional type, related chemically and pharmacologically to nitrogen mustard. The radiomimetic action of thiotepa (thiotepa (thiotepa injection) injection) is believed to occur through the release of ethylenimine radicals which, like irradiation, disrupt the bonds of DNA. One of the principal bond disruptions is initiated by alkylation of guanine at the N-7 position, which severs the linkage between the purine base and the sugar and liberates alkylated guanines.

The pharmacokinetics of thiotepa (thiotepa (thiotepa injection) injection) and TEPA in thirteen female patients (45 to 84 years) with advanced stage ovarian cancer receiving 60 mg and 80 mg thiotepa (thiotepa (thiotepa injection) injection) by intravenous infusion on subsequent courses given at 4-week intervals are presented in the following table:

Pharmacokinetic Parameters (units)	Mean± SEM
	Thiotepa		TEPA
	60 mg	80 mg	60 mg	80 mg
Peak Serum concentration (ng/mL)	1331 ± 119	1828 ± 135	273 ± 46	353 ± 46
Elimination half-life (h)	2.4 ± 0.3	2.3 ± 0.3	17.6 ± 3.6	15.7 ± 2.7
Area under the curve (ng/h/mL)	2832 ± 412	4127 ± 668	4789 ± 1022	7452 ± 1667
Total body clearance (mL/min)	446 ± 63	419 ± 56

TEPA, which possesses cytotoxic activity, appears to be the major metabolite of thiotepa (thiotepa (thiotepa injection) injection) found in human serum and urine. Urinary excretion of ¹⁴C-labeled thiotepa (thiotepa (thiotepa injection) injection) and metabolites in a 34-year old patient with metastatic carcinoma of the cecum who received a dose of 0.3 mg/kg intravenously was 63%. Thiotepa (thiotepa (thiotepa injection) injection) and TEPA in urine each accounts for less than 2% of the administered dose.

The pharmacokinetics of thiotepa (thiotepa (thiotepa injection) injection) in renal and hepatic dysfunction patients have not been evaluated. Possible pharmacokinetic interactions of thiotepa (thiotepa (thiotepa injection) injection) with any concomitantly administered medications have not been formally investigated.

Last reviewed on RxList: 11/20/2008
This monograph has been modified to include the generic and brand name in many instances.